SCHEMBL6498900

SCHEMBL6498900

Cc1ccc(S(=O)(=O)NC(=O)c2ccc3nc(C)n(Cc4ccc5c(nc(C)n5C)c4Cl)c3n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.42
PTGS1 P23219 2/20 0.42
EGFR P00533 2/20 0.39
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
FLT1 P17948 2/20 0.36
FLT4 P35916 2/20 0.36
KDR P35968 2/20 0.36
KDM4E B2RXH2 1/20 0.35
APOBEC3A P31941 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
PPARG P37231 1/20 0.34
CYP2C9 P11712 1/20 0.34
ALKBH2 Q6NS38 1/20 0.34
ALKBH5 Q6P6C2 1/20 0.34
ALKBH3 Q96Q83 1/20 0.34
FTO Q9C0B1 1/20 0.34
NR4A1 P22736 1/20 0.34
GFER P55789 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491759 0.86 PTGS2 (0.43) PTGS2PTGS1EGFRFLT1FLT4
SCHEMBL6495547 0.84 PPARG (0.53) SMN1; SMN2PPARGNPC1RAB9A
SCHEMBL6492855 0.83 PTGS2 (0.47) PTGS2PTGS1EGFRFLT1FLT4
SCHEMBL6498261 0.82 PIK3CB (0.37) SMN1; SMN2PPARGKMT2ANPC1RAB9A
SCHEMBL6299390 0.82 FLT1 (0.50) PTGS2PTGS1EGFRFLT1FLT4
SCHEMBL6501139 0.81 KDM4E (0.38) SMN1; SMN2KDM4EPPARGPTGER4KMT2A
SCHEMBL6493091 0.80 PTGS2 (0.43) PTGS2PTGS1EGFRHTTSMN1; SMN2
SCHEMBL6134163 0.80 PTGS2 (0.43) PTGS2PTGS1EGFRPKMSMN1; SMN2
SCHEMBL6299279 0.79 PTGS2 (0.44) PTGS2PTGS1EGFRHTTSMN1; SMN2
SCHEMBL6299198 0.79 PTGS2 (0.43) PTGS2PTGS1EGFRSMN1; SMN2FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US claimed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US claimed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP claimed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A PTGS2 140/4885PTGS1 86/4885EGFR 4155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.